NAPLEX North American Pharmacist Licensure Examination Practice Test
The North American Pharmacist Licensure Examination (NAPLEX) is the premier, standardized competency assessment required for pharmacist licensure in the United States. Administered by the National Association of Boards of Pharmacy (NABP), this high-stakes examination evaluates a candidate's ability to apply knowledge and make sound clinical judgments essential for safe and effective pharmacy practice. Passing the NAPLEX is a non-negotiable prerequisite for obtaining a license to practice as a pharmacist in any U.S. jurisdiction, signifying that an individual has met the rigorous, nationally recognized standard for entry-level practice. The certification validates a comprehensive understanding of pharmacotherapy, patient safety, medication distribution, and healthcare systems, serving as the final, critical gatekeeping step after the completion of an accredited Doctor of Pharmacy (PharmD) program. Its value is intrinsic to the profession, as it directly protects public health by ensuring only qualified individuals are granted the authority to dispense medications and provide patient care services.
Preguntas de Muestra
Prueba algunas preguntas para ver cómo es el examen completo.
33 de 140 respuestas incluyen una referencia verificable.
A patient starts rifampin for latent TB while taking ethinyl estradiol/norelgestromin patch, sertraline, and levothyroxine. Which mechanism drives the most urgent contraceptive counseling?
A 59-year-old woman taking warfarin has genotype results of CYP2C9 *3/*3 and VKORC1 -1639 AA. She has normal liver tests and no interacting drugs. Which initial dosing implication should the pharmacist anticipate?
A 69-year-old man with atrial fibrillation takes apixaban 5 mg twice daily. He has a major GI bleed, last dose 3 hours ago, BP 82/50, and anti-Xa activity is elevated. Which reversal approach is most appropriate if available?
A patient with suspected tumor lysis syndrome has K 6.1, phosphate 6.9, calcium 7.2, uric acid 12.8, SCr 2.2, and rising LDH after chemotherapy. Which pharmacologic action is most appropriate?
A 61-year-old with gout, CKD stage 3, and HLA-B*58:01 positivity asks about starting allopurinol after a severe flare. He is of Han Chinese ancestry. Which plan is safest?